United Kingdom · Question · Written question
UIN 153806
Tixagevimab/cilgavimab
Introduced
14 April 2022
Last action
26 April 2022 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
26 April 2022
Summary
To ask the Secretary of State for Health and Social Care, what plans he has to ensure that severely immunocompromised patients have access to Evusheld following the award of conditional marketing authorisation by the Medicines and Healthcare products Regu
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
14 April 2022
Written question
To ask the Secretary of State for Health and Social Care, what plans he has to ensure that severely immunocompromised patients have access to Evusheld following the award of conditional marketing authorisation by the Medicines and Healthcare products Regu
Source: Commons
26 April 2022
Answer
Evusheld was granted conditional marketing approval by the Medicines and Healthcare products Regulatory Agency (MHRA) on 17 March 2022. However, the positive trial data was published prior to the emergence of the Omicron variant and the MHRA’s approval ha...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2022-04-14/153806
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1457829
- uk · wq-1457829 · source updated 26 April 2022